Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2115
Peer-review started: November 29, 2021
First decision: January 12, 2022
Revised: January 17, 2022
Accepted: February 23, 2022
Article in press: February 23, 2022
Published online: March 6, 2022
Processing time: 92 Days and 21.5 Hours
Although patients with borderline ovarian tumors (BOTs) have been reported to have a better survival outcome as compared to patients with epithelial ovarian cancer (EOC), there are many risk factors of BOTs. Nomogram has been successfully applied to predict the prognosis of many cancers based on some meaningful prognostic factors, but there is no such model to study the 1, 3, 5 years’ survival of BOTs.
Served as “semi-malignant ovarian tumors”, the overall survival of BOTs after the operation has been paid high attention by the clinicians and patients. It was necessary to construct a prognostic model to assess the survival outcome of patients with BOTs.
This research aimed to develop a nomogram to predict the possibility of OS in patients with BOTs, thus contributing to making individualized treatment recommendations.
Totally 192 patients with BOTs and 374 patients with EOC were involved. Based on meaningful independent prognostic factors identified by univariate and multivariate Cox regression analyses, a nomogram model was developed to predict the 1-, 3-, and 5-year overall survival of patients with BOTs.
Compared to patients with EOC, patients with BOTs had better overall survival after 1:1 propensity score matching analysis (P value = 0.0067). We established a nomogram to predict the 1-, 3-, and 5-year OS of BOT patients. The C-index (0.959, 95% confidence interval 0.8708-1.0472) and calibration plots at 1, 3, and 5 years showed that the nomogram was a valid tool.
The current research constructed a nomogram that could accurately give a personalized prediction of the prognosis of patients with BOTs. The outcome gained from our study might provide convenience to patients and clinicians.
The nomogram developed by this study is the first to predict the 1-, 3-, and 5-year OS of women with BOTs. Moreover, it has been precisely assessed by internal validation. The results gained from our study will provide advice to make treatment planning.